Jonathan E. Rosenberg, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, discusses updates in the management of urothelial management presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, including the use of RC48 vedotin, a novel antibody-drug conjugate as well combination approaches with immune checkpoint inhibitors and chemotherapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

свернуть